We are thrilled to announce the release of the 2016 World Orphan Drug Congress USA brochure!
Following 5 years of success, the 6th Annual World Orphan Drug Congress USA is once again gearing up to bring together stakeholders from all over the world. From humble beginnings as a small conference that brought together the few pioneers spearheading the progress in orphan drugs development it became known as the event that brought this community together. It is testament to how the industry has grown that now there are 3 simultaneous conference streams and an exhibition hall of over 40 stands at the Washington Hilton in D.C.
Here are 11 reasons why you should not only download the World Orphan Drug Congress USA brochure, but you should also be in Washington D.C. on April 20-22 next year.
Get your copy today to find out more about what we are discussing, who is speaking and who is sponsoring.
- Discuss international orphan drug policy developments from regulators and stakeholders in the U.S., Europe, Malaysia, Chile, Japan, Canada and the Philippines.
- Hear about the advocacy work done by patient groups from Argentina, Mexico, Brazil, Japan and Malaysia.
- Understand the ethics of Expanded Access in the US and what ‘Right To Try’ really is from Art Caplan, Head of the Division of Medical Ethics at the NYU Langone Medical Center.
- Learn about the challenges faced by physicians in the rare disease space and how industry can engage Key Opinion Leaders strengthening patient outreach and clinical trial performance.
- Understand how the 21st Century Cures and Innovations Acts can facilitate faster treatment development for devastating diseases or increase the risk of approving drugs that are not effective or safe from Novartis, NORD, Ultragenyx and the FDA.
- Join James Greenwood, from the Biotechnology Industry Organization, Ian Phillips from the Keck Graduate Institute of Applied Life Sciences and Steve Usdin from BioCentury in the pricing debate for orphan drugs and hear about appropriate pricing models for a one-time transformational gene therapy vs. orphan drugs for life.
- Hear Alvin Shih from Retrophin explain the accelerated approval (subpart H) pathway and its relevance to rare disease drug development.
- Uncover the latest innovations in our Pitch & Partner session. We’re bringing even more companies than last year. Meet with 35 biotechs looking for partners.
- Explore how stakeholders are looking to improve the processes behind orphan drug development when Yann Le Cam shares Europe’s Medicine Adaptive Pathways to Patients (MAPPs).
- Join Biomarin, Alexion, PTC, Veloxis, Novartis, EURORDIS and the NIH at the Rare Disease Advocacy World discuss the nitty gritty of R&D, regulatory, patients’ rights, bioethics and collaboration.
- Examine how Aetna is creating a systematic process to orphan drug discovery by starting with the unmet needs of payers and patients.
As always, the earlier you book the more you save. So register today!
See you there!